FDA Updates Orlistat Warnings
The FDA issued a drug safety communication approving a label change that warns about the risk of kidney stones or kidney injury with the over-the-counter (OTC) weight loss drug orlistat (Alli), the agency said Wednesday.
The label now recommends that consumers with a history of kidney disease or kidney stones consult a healthcare provider before using the drug.
Reports of Kidney Injury
The FDA advised clinicians to inform patients about reports of acute kidney injury (AKI), hyperoxaluria, calcium oxalate nephrolithiasis, or oxalate nephropathy linked to orlistat. Patients should also stop taking the drug if they develop symptoms like back or groin pain, painful urination, blood in urine, feet or leg swelling, or less frequent urination.
These events are rare, the agency noted. Mild cases of AKI may be reversible, but untreated severe cases can be fatal.
Fuente: https://www.medpagetoday.com/primarycare/obesity/121703
Join the doctors who get the most relevant medical news, curated by specialty, every week — no spam, unsubscribe anytime.
